Rheumnow Podcast

Day 3 Recap ACR Convergence 2026

Belimumab and Rituximab for SLE A Successful Trial
CAR-T in Rheumatoid Arthritis will it stay
Head to Head JAK vs JAK in RA
JAK1 TYK2i beats Tofacitinib in Active RA
JAKi Cardiovascular Safety in Younger Adults
Low PREVENT Score, Real Risk Coronary Calcium and Heart Failure in Lupus
New Therapy for Fibromyalgia
One dose for every body Rethinking drug exposure
Tirzepitide Add on or start together in PsA
Treating joints and weight together TOGETHER PSA
Two targets or one CAR-T in Lupus Nephritis
Interstitial Pneumonia with Autoimmune Features (IPAF)

Can a smartphone identify inflammatory arthritis
Can Gut Candida Trigger Rheumatoid Arthritis Maybe
CAR T Without Lymphodepletion
First theranostic approach to treat difficult-to-treat RA
Lifestyle Interventions and Biological Effects in RA
New Rheumatic Disease after CAR-T
Pain in axSpA may Reflect More than Inflammation
Preliminary PK, PD, Clinical and Safety Data of NK019 in Myositis
Real World of SARD ILD
Use of JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease
VALORous Efforts in Dermatomyositis Interstitial Lung Disease
Who Manages Fibromyalgia

Proteinuria Another one bites the dust in lupus nephritis
Silent Drifts Non adherence and inflammation in SLE
The Lupus Outcomes Gap
Myositis Hurts
Nociplastic Pain in axSpA
GLP-1 A game changer for lung health
Incidence of Obesity Overweight in PsA Four in Five
Retatrutide for knee osteoarthritis and obesity
Tirzepitide Add on or start together in PsA
BE BOLD Bimekizumab beats Risankizumab in PsA

Join RheumNow for a live recap of Day 3 of ACR Convergence 2026. 
Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice.
Panelist: 

Dr. Bella Mehta

Dr. Brian Jaros 

Dr. Henrique Dalomin 

Dr. Sheila Reyes

 

Moderator: Dr. David Liew

SGLT2 Inhibitors in Lupus Nephritis
Not Seronegative Rheumatoid Arthritis-Interstitial Lung Disease
Anti-CCP Antibody Testing on the Spot
Lessons learned from ReBioLup data in Lupus Nephritis

RA-ILD and Lung Cancer
Good News and Bad News for CCP+ at Risk for RA
Sex Differences in Psoriatic Arthritis
Drugs in Lupus Nephritis Save Kidney Function, Increase Survival
What Happens to Muscle Mass and Muscle Strength in RA
GLP-1 Agonists in Psoriatic Arthritis
Infliximab Biosimilar Switching

Biologic Response in PsA
Block the Antibody Lupus, Myositis, Scleroderma
Can GLP-1 Therapy Help PsA Beyond Losing Weight
Can we do Pulmonary Testing at Home
Fibromyalgia and Depression in Rheumatoid Arthritis
Hydroxychloroquine Blood Levels and Retinopathy Risk
JAK vs TNFi in RA Can Biomarkers Help us Choose
Menopause in RA An Under Recognized Burden
New Treatments in ILD
Rosnilimab in RA Why May it be Relatively Safe
Statins and eGFR in SLE
Four Joint Fibromyalgia Warning

Day 2 of ACR Convergence 2026. Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice. Drs. Adela Castro, Antoni Chan, Eric Dein Moderator: Dr. David Liew

Combination Therapy in Rheumatoid Arthritis
Study Design and Comparative Effectiveness in RA
Difficult to Treat RA
What are our goals, really, in ILD
New Treatments in Scleroderma Early Days
A New Way to Measure Disease Activity in Rheumatoid Arthritis